Form 4: Ligand Pharmaceuticals Director Receives Equity Compensation, Including RSUs and Stock Options

Martine Zimmermann, a Director at Ligand Pharmaceuticals Inc., acquired 1,209 restricted stock units and 5,783 non-qualified stock options as part of her compensation, while also having 188 shares withheld for tax liabilities.

Summary

• Martine Zimmermann, a Director of Ligand Pharmaceuticals Inc. (LGND), acquired 1,209 shares of common stock in the form of restricted stock units (RSUs) on June 6, 2025, granted by the Board of Directors at their annual meeting.
• These RSUs represent a contingent right to receive one share of common stock and will fully vest on the earlier of the date of the next annual meeting of the Company stockholders following the grant date or the first anniversary of the grant date (June 6, 2026).
• Concurrently, 188 shares of common stock were disposed of at a price of $105.99 per share to cover tax liabilities arising from the settlement of restricted stock units.
• Ms. Zimmermann also acquired 5,783 non-qualified stock options on June 6, 2025, with an exercise price of $105.99 per share and an expiration date of June 6, 2035.
• These stock options will fully vest under the same conditions as the RSUs: the earlier of the next annual meeting of stockholders following the grant date or the first anniversary of the grant date (June 6, 2026).
• Following these transactions, Ms. Zimmermann directly beneficially owns 4,558 shares of common stock and 5,783 non-qualified stock options.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director received equity compensation, aligning their interests with shareholders and indicating continued commitment to the company. The tax withholding is a standard part of equity compensation and does not detract from the overall positive nature of the grants.

Positives

• The grant of 1,209 restricted stock units (RSUs) to a director aligns their interests with shareholders and serves as a form of equity compensation.
• The acquisition of 5,783 non-qualified stock options provides the director with potential future upside tied to the company's stock performance.
• The compensation package indicates continued commitment and incentivization for the director's role within the company.

Negatives

• 188 shares of common stock were withheld by the Issuer to cover tax liabilities, resulting in a reduction of directly held shares.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's financial performance or strategic outlook, focusing solely on an insider's equity compensation and transactions.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, specifically equity compensation for a director. It does not provide information relevant to broader industry trends or competitive positioning within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The grant of equity compensation to a director aligns their interests with those of shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The 1,209 restricted stock units (RSUs) are expected to vest on the earlier of the next annual meeting of Ligand Pharmaceuticals Inc. stockholders following June 6, 2025, or June 6, 2026.
• The 5,783 non-qualified stock options are expected to vest on the earlier of the next annual meeting of Ligand Pharmaceuticals Inc. stockholders following June 6, 2025, or June 6, 2026.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership, Corporate Governance